November 2, 2020
Today, we are pleased to announce that Hemispherian AS has been awarded the prestigious Innovation Project grant from the Research Council of Norway. The grant, 14.6 MNOK, will be administered over the next two years and will allow us to advance our lead therapeutics into clinical trials.
“We are thrilled that the research council has selected Hemispherian. This grant will enable Hemispherian to significantly accelerate the development of our drug pipeline. We anticipate that our therapeutics will dramatically improve life expectancy and quality of life for many cancer patients.”
— Zeno Albisser, CEO
The awarded innovation project will be completed in collaboration with researchers and clinicians from the University of Oslo, Oslo University Hospital, and the Norwegian University of Science and Technology.
We would like to give a warm thank you to the Life Science Cluster, Norway Health Tech, Oslo Cancer Cluster and Sharelab for their support of Hemispherian.